Insight Molecular Diagnostics Q3 2026 net loss narrows 67% year over year to $3.6 million
- Insight Molecular Diagnostics’ Q3 2026 net loss narrowed 67% year over year to $3.6 million.
- Revenue more than doubled year over year to $559,000.
- Operating expenses fell 63% year over year to $4.1 million, including a $4.1 million noncash contingent-consideration fair-value gain.
- Quarter-end cash, cash equivalents and restricted cash dropped 37% from Q2 2026 to $11.8 million.
- Management expects to submit its complete response to the FDA’s additional-information request for GraftAssureDx before the January 21, 2027 deadline.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.